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INTRODUCTION
Ubiquitin carboxyl-terminal esterase L1 (UCHL1), also 
known as ubiquitin carboxy-terminal hydrolase and 
neuron-specific protein gene product 9.5 (PGP 9.5), is 
one of the most abundant proteins in the brain and 
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ABSTRACT
Background:  Cataract  is  characterized  by  light-scattering  protein  aggregates.  The 
  ubiquitin-proteasome system has been proposed a role in proteolytic removal of these protein 
aggregates. Ubiquitin carboxyl-terminal esterase L1 (UCHL1) is a de-ubiquitinating enzyme with 
important functions in recycling of ubiquitin. A protective role of the p.S18Y polymorphism of the 
UCHL1 gene has been shown in Parkinson`s disease. The current study aimed to examine possible 
effects on cataract formation.
Methods:  Patients with cataract (n = 493) and controls (n = 142) were analyzed for the UCHL1 p.S18Y 
polymorphism using dynamic allele-specific hybridization.
Results:  Significant differences were observed in allele and genotype frequencies of the p.S18Y 
polymorphism between controls and cataract patients, where a positive UCHL1 allele A carrier 
status was associated with the cataract diagnosis (adjusted OR 1.7 [95% CI = 1.1–2.6] p = 0.02). No 
significant differences were seen in genotype distribution when stratifying for type of cataract. Nor 
did the mean age at cataract surgery differ between genotypes.
Conclusion:  The current study does not support a protective role for the UCHL1 S18Y polymor-
phism in cataract development, but may instead suggest a disease-promoting effect.
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therefore used as a sensitive neural marker.1 It belongs 
to the family of de-ubiquitinating proteins (DUBs) and 
is as such a component of the ubiquitin-proteasome 
system (UPS). The major function of UCHL1 can be 
described  as  mono-ubiquitin  recycling,  helping  to 
maintain monomeric ubiquitin levels. Interestingly, as 
a dimer it reverses its function and becomes an ubiq-
uitin-protein ligase resembling the E3 enzymes of the 
UPS.2 The UCHL1 gene gained special interest after it 
had been linked to a family with an autosomal domi-
nant missense mutation (p.I93M) causing Parkinson´s 
disease (PD).3 While this mutation seems to be very 
rare, another, more frequent UCHL1 polymorphism has 
been discovered in the course of a search for p.I93M 
mutants. The p.S18Y variant (c.53C >A, rs id 5030732) 
shows  diminished  dimerization  and  ligase  activity.2 
It has been ascribed a protective role for PD by some 
authors,4–6 while other studies found no association with 
the disease.7 For other neurodegenerative diseases, the 
reports  are  similarly  contradictive.  In  Huntington’s 
disease, the UCHL1 p.S18Y variant is linked to age at 
onset.8 For Alzheimer’s disease (AD), a Chinese study 
has demonstrated lower frequencies of the A allele and 
the AA genotype in female AD patients as compared to 
female controls.9 However, other studies could not find 
an association between UCHL1 genotypes and AD.10,11
UCHL1 is expressed mostly in neural tissues, but 
there are also some reports of other non-neural tissues 
expressing UCHL1.12 There are few reports on UCHL1 
expression in the eye. In the retina, expression seems to 
be most abundant in the horizontal and ganglion cells.13 
To our knowledge there is only one report on UCHL1 
expression in the lens, showing increased expression in 
the lens epithelial cells of atopic cataracts.14 UPS activity 
is present in the aging lens and seems to diminish both 
with increasing turbidity and from the lens epithelium 
to the nucleus.15 Cataract is opacification of the eye lens 
resulting from the aggregation of lens proteins, mainly 
the so called crystallins. The UPS has been suggested to 
play a pivotal role in preventing the formation of such 
light-scattering protein aggregates by proteolytic deg-
radation.16 The present study thus aimed to investigate 
if there is an association between the UCHL1 p.S18Y 
polymorphism and cataract.
PATIENTS AND METHODS
After informed consent, patients with senile cataract 
and  control  individuals  were  recruited  from  two 
ophthalmic clinics in the town of Tartu and the South-
Estonian area. The study was approved by the Ethical 
Commission at the University of Tartu, Estonia. Prior to 
surgery, the type of cataract was determined using bio-
microscopy and ophthalmoscopy. Secondary cataracts 
were excluded. The case group included 493 cataract 
patients (76 with nuclear, 154 with cortical, 116 with 
posterior subcapsular, and 147 with mixed opacities). 
The reported age is close to the time of surgery. For 
control subjects, only individuals above the age of 60 
years were included, yielding 142 individuals with a 
mean age (±SD) of 68 ± 5.3 (range 61 to 90 years). Mean 
age  in  the  cataract  group  was  72 ± 8.7  years  (range 
47–93 years).
The UCHL1 (gene map locus 4p14; [Entrez gene 
ID: 7345]) p.S18Y, c.53C>A polymorphism (rs5030732) 
was  analyzed  using  the  Dynamic  Allele  Specific 
Amplification  (DASH)  tehnology  as  described  ear-
lier.17  The  PCR  were  carried  out  with  HotStarTaq 
DNA Polymerase® (QIAGEN, Hilden, Germany) in a 
final volume of 25 µl, containing 5–20 ng of template 
DNA. Optimal conditions were: 1 mM MgCl2, 0.2 mM 
dNTPs, 0.02 U Taq polymerase, 0.16 pmol/µl of the 
forward  biotinylated  primer  (5’  Biotin-GCCGCCTT-
GTCTCCTCTCAGCAG3’)  and  0.78  pmol/µl  of  the 
reverse  primer  (5’GTCACTGGCCTGCGACCCC3’), 
(Invitrogen, Paisley, UK) in 1 x PCR buffer (Roche, 
Mannheim, Germany). The cycling profile was: 15 min 
at 95 °C, then 39 cycles: 30 sec at 95°C, 45 sec at 60°C, 
45 sec at 72°C and finally 10 min at 72 °C. To identify 
UCHL1 alleles the probe 5’GACAGAAACGCACTTGT-
Rox3’ (MWG Biotech, London, United Kingdom) was 
used. The accuracy of the DASH method was verified 
by DNA sequencing of 15 individuals representing the 
different UCHL1 genotypes (five of each genotype).
Primary analyses compared differences between the 
cataract patients and control subjects regarding age, 
sex, genotype and allele frequencies using Student’s 
t-test, Fisher’s exact test and Pearson’s chi-square test. 
Secondary analysis of UCHL-1 allele A-carrier status 
was performed with a binary logistic regression model 
with diagnosis (cataract versus control) as dependent 
variable and allele positivity, age and sex as indepen-
dent variables. Significance was set at P<0.05. SPSS 17.0 
(SPSS Inc., Chicago, Il) was used as statistic software.
RESULTS
Mean age and sex distribution for the cataract and 
control group is shown along with genotype distri-
bution, allele frequency and UCHL1 allele A-carrier 
status in Table 1. The allele frequencies found in this 
study were in accordance with previous reports on 
caucasian populations, including neighbouring coun-
tries (see Swedish study by Belin et al.).4,6 The geno-
type distribution for both cataract and control group 
were  in  Hardy-Weinberg  equilibrium.  Significant 
differences in genotype and allele distributions were 
seen  between  the  control  group  and  the  cataract UCHL1 S18Y polymorphism in cataract    77
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patients. A  positive  UCHL1  allele A-carrier  status 
was significantly higher among cataract patients as 
compared to the control group (p = 0.015). This asso-
ciation  remained  after  correcting  for  age  and  sex, 
using a binary logistic model (adjusted OR 1.7 [95% 
CI = 1.1–2.6] p = 0.02), see Table 2. Stratification of the 
data according to type of cataract showed a consis-
tently higher percentage of both homozygotes and 
heterozygotes for the UCHL1 allele A as compared 
to controls. This overrepresentation was statistically 
significant  for  posterior  subcapsular  and  mixed 
cataract only (Table 3). Age at surgery did not vary 
significantly between UCHL1 p.S18Y genotypes, as 
evident in Table 4.
DISCUSSION
It has been shown that with ageing of the lens, tissue-
specific crystallin proteins are subjected to a large num-
ber of posttranslational changes, including oxidative 
modifications.18
The resulting conformational changes cause pro-
tein aggregation and subsequent light scatter, hence 
cataract.19 In mammalian cells, including lens cells/
lens fibers, the ubiquitin-proteasome system (UPS) is 
the major proteolytic system for degradation of aber-
rant proteins. It has been shown that mildly oxidized 
crystallin proteins are better substrates for the UPP 
than native proteins, supporting a role for the UPS in 
clearing the lens from defect proteins.16
Aggregation of aberrant proteins is also a hallmark 
of  several  neurodegenerative  diseases,  including 
Alzheimer’s (AD), Huntington’s (HD), and Parkinson’s 
(PD) diseases. Accordingly, the UPS has been suggested 
to play a major role in preventing the formation of path-
ological protein aggregates in these diseases as well.20
A number of reports have demonstrated a pro-
tective effect of the UCHL1 p.S18Y polymorphism 
against sporadic PD in different populations,4,6,21,22 
although conflicting data exist.23 As for AD, data on 
UCHL1 genotype frequencies and its effect on risk 
of AD  is  scarce  and  conflicting.9,10  To  our  knowl-
edge, there are no previous reports on the effect of 
the UCHL1 p.S18Y genotype distribution in cataract 
patients.
Cataract is a strongly age-dependent disorder; in 
the Beaver Dam Eye Study, the 5-year cumulative 
incidence  of  nuclear  cataract  increased  from  2.9% 
in persons aged 43 to 54 years at baseline to 40% in 
those aged 75 or older.24 In this study, the reported 
age for the cataract patients corresponds to the year 
of surgery. While it is not self-evident that this age 
corresponds to the age at onset, we find it reason-
able to assume that the two variables correlate, at 
least at the group level. For an age-dependent dis-
ease,  one  can  assume  that  carriers  of  a  protective 
gene variant should on average have a higher age at 
onset. However, when stratifying the cataract group 
according to UCHL1 p.S18Y genotype, there was no 
significant difference in mean age, neither indicating 
a protective nor disease-promoting effect. In contrast, 
the UCHL1 allele A frequency was significantly higher 
in the cataract group compared to the control group. 
After stratifying for clinically different types of cata-
ract, significance was lost for nuclear and cortical cat-
aract. If this is a random effect due to sample size or 
if this reflects pathophysiological differences between 
cataract subgroups cannot be safely concluded from 
our data. Nevertheless, these findings may suggest a 
possible disease-promoting effect and argue against a 
protective effect of the UCHL1 p.S18Y polymorphism 
in  cataract.  However,  the  associations  found  were 
quite weak and argue against any pivotal role for the 
TABLE 1  Demographic and genetic characteristics of patients with cataract and controls.
  Control Cataract p-value
Number (total) 142 493  
Age (years), mean±SD 68 ± 5.3 72 ± 8.7 <0.001*
Sex female/male, n (%) 101/41 (71.1/28.9) 342/151 (69.4/30.6) 0.39†
UCHL1
Genotype frequencies, n (%)
AA 3 (2.1) 20 (4.1) 0.039‡
AC 31 (21.8) 153 (31.0)  
CC 108 (76.1) 320 (64.9)  
Allele frequency, n (%)
A N = 37 (13.0) N = 193 (19.6) 0.011†
C N = 247 (87.0) N = 793 (80.4)  
Allele A-carrier, n (%) N = 37 (23.90) N = 193 (35.10) 0.015†
* Student’s t-test
† Fisher’s exact test
‡ Chi-2 test, Pearson’s78    Thiemo Rudolph et al.
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UCHL1 p.S18Y polymorphism in cataract disease. In 
addition, a limitation of the present study is that mul-
tiple loci or several diseases were not tested.
Given the complexity of the UPS and its essential 
functions in all organ systems, it is not surprising 
that it has been implicated in the pathophysiology 
of a large number of both congenital and acquired 
diseases and in the process of ageing itself.25,26 Several 
polymorphisms of the UPS and associated proteins 
have been described, the majority of which are dis-
ease-promoting.27,28 On the contrary, the p.S18Y poly-
morphism of the UCHL1 gene appears to confer at 
least a moderate protection in Parkinson’s disease.29
In this study, the p.S18Y variant was underrepre-
sented in the control group, hence excluding a pro-
tective role of this UCHL1 polymorphism in cataract. 
Considering the multiple functions of UCHL1 with 
regard  to  the  UPS,  such  as  recycling  of  ubiquitin, 
the processing of ubiquitin precursors and ubiquitin 
ligase activity,30 it is possible that separate functions of 
the enzyme have opposed effects in the pathogenesis 
of different diseases. In neurodegenerative disorders 
characterized by protein aggregation, recent studies 
have suggested that it is not the protein aggregates in 
themselves that lead to neuronal death, but rather the 
preceding oligomers that are toxic to the neurons.31 
Similar toxic effects could also be damaging to the 
lens, especially in the more metabolically active parts 
such as the epithelium and the superficial lens fibers. 
In the metabolically quiescent lens nucleus however, 
light-scattering effects of large aggregates of lens pro-
teins should be a more important pathogenetic feature 
than in the outer lens regions and also as compared to 
neuronal tissue.
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